drugset / Trial / NCT00937664

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

NCT00937664

Phase 1 Terminated 24 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.

Timeline

Start
2009-07
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7762 Small molecule Intravenous
Background Gemcitabine Small molecule Intravenous

Indications